NASDAQ:BFRI Biofrontera Q2 2026 Earnings Report $1.08 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.08 0.00 (0.00%) As of 05:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Biofrontera EPS ResultsActual EPSN/AConsensus EPS -$0.11Beat/MissN/AOne Year Ago EPSN/ABiofrontera Revenue ResultsActual RevenueN/AExpected Revenue$9.50 millionBeat/MissN/AYoY Revenue GrowthN/ABiofrontera Announcement DetailsQuarterQ2 2026Date8/12/2026TimeAfter Market ClosesConference Call DateWednesday, August 12, 2026Conference Call Time12:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Biofrontera Earnings HeadlinesBiofrontera (NASDAQ:BFRI) Upgraded to Hold at Wall Street ZenJuly 18, 2026 | americanbankingnews.comBiofrontera’s Acne PDT Trial Completion: What Investors Should Watch NextJuly 8, 2026 | tipranks.comHe bet half his $9 billion on ONE stockOne of the most successful fund managers of the past 50 years put more than $4.5 billion - over half his fund - into a single, little-known company. His firm then bought more shares for 61 straight trading days, and the former CEO of Google soon struck a nine-figure partnership with the same company. This company controls nearly a million acres of scarce, irreplaceable minerals now protected by a White House executive order signed January 14, 2026. It has already outperformed Apple, Amazon, and the S-P 500 combined - and Whitney Tilson believes the biggest gains are still ahead.July 22 at 1:00 AM | Stansberry Research (Ad)Biofrontera’s Phase III Actinic Keratosis Study Nears Data Payoff for InvestorsJuly 7, 2026 | tipranks.comBiofrontera Shareholders Approve Director Elections and Equity PlanJune 17, 2026 | tipranks.comBiofrontera Inc. (BFRI) Shareholder/Analyst Call Prepared Remarks TranscriptJune 11, 2026 | seekingalpha.comSee More Biofrontera Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Biofrontera? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biofrontera and other key companies, straight to your email. Email Address About BiofronteraBiofrontera (NASDAQ:BFRI) AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue. The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis. Ameluz is used in combination with the BF-RhodoLED® lamp, a medical device designed to emit the precise wavelength of red light required to activate the gel. This integrated pharmaceutical–device approach underpins the company’s position in the PDT market. Founded in 1997 and headquartered in Leverkusen, Germany, Biofrontera maintains operations in multiple geographies, including a U.S. subsidiary established to support commercialization efforts in North America. Beyond its approved indications, the company is exploring additional dermatological uses for its photodynamic platform and is engaged in discussions with regulatory authorities and commercial partners to expand its presence in key markets such as Canada, Turkey and beyond. Biofrontera’s management team brings together expertise in dermatology, pharmaceutical development and medical device manufacturing. The company continues to invest in its pipeline, seeking to leverage its PDT technology for new indications and to forge strategic partnerships that will broaden access to its therapies worldwide.View Biofrontera ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Why Apple Could Be the Last One Standing in the Tech Wreck3M's Redemption Arc: Can Q2 Earnings Change the Narrative?Texas Power Play: Hut 8 Sparks a $9.8B AI Infrastructure DealMoog Is More Than a Missile Maker, and Wall Street Is NoticingAlphabet Is Planning a New AI Chip. Here's Why It Matters Ahead of EarningsConfidence Is Back, But Earnings Show the Consumer Is Being PickyIndustrial and Utility Giants Boost Dividends as Data Center Tailwinds Build Upcoming Earnings RTX (7/23/2026)Lockheed Martin (7/23/2026)Newmont (7/23/2026)Intel (7/23/2026)Nokia (7/23/2026)Relx (7/23/2026)SAP (7/23/2026)STMicroelectronics (7/23/2026)T-Mobile US (7/23/2026)Comfort Systems USA (7/23/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
